MAP2K6 Human (-)-alpha-phellandrene increases expression EXP 6480464 alpha phellandrene results in increased expression of MAP2K6 mRNA CTD PMID:25075043 MAP2K6 Human (-)-epigallocatechin 3-gallate multiple interactions EXP 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP2K6 mRNA CTD PMID:22079256 MAP2K6 Human (S)-nicotine increases expression ISO Map2k6 (Rattus norvegicus) 6480464 Nicotine results in increased expression of MAP2K6 mRNA CTD PMID:20426880 MAP2K6 Human 1,1,1-Trichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane multiple interactions EXP 6480464 o and p'-DDT promotes the reaction [MAP2K6 protein results in increased activity of CREBBP protein] CTD PMID:22609851 MAP2K6 Human 1,2-dimethylhydrazine decreases expression ISO Map2k6 (Mus musculus) 6480464 1 and 2-Dimethylhydrazine results in decreased expression of MAP2K6 mRNA CTD PMID:22206623 MAP2K6 Human 17alpha-ethynylestradiol decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Ethinyl Estradiol results in decreased expression of MAP2K6 mRNA CTD PMID:15834898 MAP2K6 Human 17alpha-ethynylestradiol affects expression ISO Map2k6 (Rattus norvegicus) 6480464 Ethinyl Estradiol affects the expression of MAP2K6 mRNA CTD PMID:26865667 MAP2K6 Human 17beta-estradiol decreases expression ISO Map2k6 (Mus musculus) 6480464 Estradiol results in decreased expression of MAP2K6 mRNA CTD PMID:25210133 MAP2K6 Human 17beta-estradiol decreases expression EXP 6480464 Estradiol results in decreased expression of MAP2K6 mRNA CTD PMID:31614463 MAP2K6 Human 17beta-estradiol multiple interactions EXP 6480464 [Estradiol co-treated with TGFB1 protein] results in decreased expression of MAP2K6 mRNA and [Progesterone co-treated with Estradiol] results in increased expression of MAP2K6 mRNA CTD PMID:17404688 and PMID:30165855 MAP2K6 Human 17beta-estradiol multiple interactions ISO Map2k6 (Mus musculus) 6480464 ESR1 protein promotes the reaction [Estradiol results in decreased expression of MAP2K6 mRNA] CTD PMID:25210133 MAP2K6 Human 2,3,7,8-tetrachlorodibenzodioxine decreases expression ISO Map2k6 (Mus musculus) 6480464 Tetrachlorodibenzodioxin results in decreased expression of MAP2K6 mRNA CTD PMID:14708085 MAP2K6 Human 2,3,7,8-tetrachlorodibenzodioxine affects expression EXP 6480464 Tetrachlorodibenzodioxin affects the expression of MAP2K6 mRNA CTD PMID:22574217 MAP2K6 Human 2,3,7,8-tetrachlorodibenzodioxine affects expression ISO Map2k6 (Mus musculus) 6480464 Tetrachlorodibenzodioxin affects the expression of MAP2K6 mRNA CTD PMID:21570461 and PMID:28922406 MAP2K6 Human 2,3,7,8-tetrachlorodibenzodioxine increases expression ISO Map2k6 (Rattus norvegicus) 6480464 Tetrachlorodibenzodioxin results in increased expression of MAP2K6 mRNA CTD PMID:21215274 and PMID:33387578 MAP2K6 Human 2,3,7,8-tetrachlorodibenzodioxine multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 AHR protein alternative form inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MAP2K6 mRNA] CTD PMID:21215274 MAP2K6 Human 2,4-dibromophenyl 2,4,5-tribromophenyl ether decreases expression EXP 6480464 2 more ... CTD PMID:26705709 MAP2K6 Human 2-nitrofluorene decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 2-nitrofluorene results in decreased expression of MAP2K6 mRNA CTD PMID:22484513 MAP2K6 Human 3,3',4,4'-tetrachlorobiphenyl multiple interactions ISO Map2k6 (Mus musculus) 6480464 3 more ... CTD PMID:19467301 MAP2K6 Human 3,4-methylenedioxymethamphetamine increases expression ISO Map2k6 (Mus musculus) 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in increased expression of MAP2K6 mRNA CTD PMID:26251327 MAP2K6 Human 3,4-methylenedioxymethamphetamine increases methylation ISO Map2k6 (Mus musculus) 6480464 N-Methyl-3 and 4-methylenedioxyamphetamine results in increased methylation of MAP2K6 promoter CTD PMID:26251327 MAP2K6 Human 4,4'-diaminodiphenylmethane increases expression ISO Map2k6 (Mus musculus) 6480464 4 and 4'-diaminodiphenylmethane results in increased expression of MAP2K6 mRNA CTD PMID:18648102 MAP2K6 Human 4-hydroxyphenyl retinamide multiple interactions EXP 6480464 Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAP2K6 protein] CTD PMID:16407847 MAP2K6 Human 4-hydroxyphenyl retinamide increases phosphorylation EXP 6480464 Fenretinide results in increased phosphorylation of MAP2K6 protein CTD PMID:16407847 MAP2K6 Human 6-propyl-2-thiouracil decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Propylthiouracil results in decreased expression of MAP2K6 mRNA CTD PMID:30047161 MAP2K6 Human afimoxifene decreases response to substance EXP 6480464 MAP2K6 results in decreased susceptibility to afimoxifene CTD PMID:21233418 MAP2K6 Human aflatoxin B1 affects expression EXP 6480464 Aflatoxin B1 affects the expression of MAP2K6 protein CTD PMID:20106945 MAP2K6 Human aflatoxin B1 decreases expression EXP 6480464 Aflatoxin B1 results in decreased expression of MAP2K6 mRNA CTD PMID:21632981 more ... MAP2K6 Human aflatoxin B1 increases methylation EXP 6480464 Aflatoxin B1 results in increased methylation of MAP2K6 gene CTD PMID:27153756 MAP2K6 Human aldehydo-D-glucose multiple interactions EXP 6480464 [MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Glucose CTD PMID:27278863 MAP2K6 Human all-trans-retinoic acid decreases expression EXP 6480464 Tretinoin results in decreased expression of MAP2K6 mRNA CTD PMID:21934132 MAP2K6 Human all-trans-retinoic acid increases expression EXP 6480464 Tretinoin results in increased expression of MAP2K6 mRNA CTD PMID:33167477 MAP2K6 Human alpha-phellandrene increases expression EXP 6480464 alpha phellandrene results in increased expression of MAP2K6 mRNA CTD PMID:25075043 MAP2K6 Human amino acid multiple interactions EXP 6480464 [MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Amino Acids CTD PMID:27278863 MAP2K6 Human ammonium chloride affects expression ISO Map2k6 (Rattus norvegicus) 6480464 Ammonium Chloride affects the expression of MAP2K6 mRNA CTD PMID:16483693 MAP2K6 Human amphetamine decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Amphetamine results in decreased expression of MAP2K6 mRNA CTD PMID:30779732 MAP2K6 Human andrographolide multiple interactions EXP 6480464 andrographolide inhibits the reaction [VEGFA protein results in increased phosphorylation of MAP2K6 protein] CTD PMID:24814888 MAP2K6 Human anthra[1,9-cd]pyrazol-6(2H)-one multiple interactions EXP 6480464 pyrazolanthrone inhibits the reaction [[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] CTD PMID:27278863 MAP2K6 Human antirheumatic drug increases expression EXP 6480464 Antirheumatic Agents results in increased expression of MAP2K6 mRNA CTD PMID:24449571 MAP2K6 Human aristolochic acid A decreases expression EXP 6480464 aristolochic acid I results in decreased expression of MAP2K6 mRNA CTD PMID:33212167 MAP2K6 Human arsane affects methylation EXP 6480464 Arsenic affects the methylation of MAP2K6 gene CTD PMID:25304211 MAP2K6 Human arsane decreases expression EXP 6480464 Arsenic results in decreased expression of MAP2K6 mRNA CTD PMID:29248574 MAP2K6 Human arsenic atom affects methylation EXP 6480464 Arsenic affects the methylation of MAP2K6 gene CTD PMID:25304211 MAP2K6 Human arsenic atom decreases expression EXP 6480464 Arsenic results in decreased expression of MAP2K6 mRNA CTD PMID:29248574 MAP2K6 Human arsenite(3-) increases expression ISO Map2k6 (Mus musculus) 6480464 arsenite results in increased expression of MAP2K6 mRNA CTD PMID:18191166 MAP2K6 Human arsenous acid multiple interactions EXP 6480464 Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAP2K6 protein CTD PMID:16818652 MAP2K6 Human arsenous acid decreases expression EXP 6480464 Arsenic Trioxide results in decreased expression of MAP2K6 mRNA CTD PMID:26705709 MAP2K6 Human arsenous acid affects response to substance ISO Map2k6 (Mus musculus) 6480464 MAP2K6 protein affects the susceptibility to Arsenic Trioxide CTD PMID:16818652 MAP2K6 Human arsenous acid multiple interactions ISO Map2k6 (Mus musculus) 6480464 MAP2K6 protein promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK14 protein] CTD PMID:16818652 MAP2K6 Human atazanavir sulfate multiple interactions EXP 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 MAP2K6 Human atazanavir sulfate decreases expression EXP 6480464 Atazanavir Sulfate results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 MAP2K6 Human atrazine affects methylation ISO Map2k6 (Rattus norvegicus) 6480464 Atrazine affects the methylation of MAP2K6 gene CTD PMID:28931070 MAP2K6 Human azathioprine decreases expression EXP 6480464 Azathioprine results in decreased expression of MAP2K6 mRNA CTD PMID:22623647 MAP2K6 Human benzene decreases expression EXP 6480464 Benzene results in decreased expression of MAP2K6 mRNA CTD PMID:33064461 MAP2K6 Human benzene increases expression ISO Map2k6 (Mus musculus) 6480464 Benzene results in increased expression of MAP2K6 mRNA CTD PMID:34624356 MAP2K6 Human benzo[a]pyrene decreases expression ISO Map2k6 (Mus musculus) 6480464 Benzo(a)pyrene results in decreased expression of MAP2K6 mRNA CTD PMID:19770486 and PMID:21569818 MAP2K6 Human benzo[a]pyrene decreases methylation ISO Map2k6 (Mus musculus) 6480464 Benzo(a)pyrene results in decreased methylation of MAP2K6 intron CTD PMID:27901495 MAP2K6 Human benzo[a]pyrene decreases expression EXP 6480464 Benzo(a)pyrene results in decreased expression of MAP2K6 mRNA CTD PMID:20106945 more ... MAP2K6 Human benzo[a]pyrene affects expression EXP 6480464 Benzo(a)pyrene affects the expression of MAP2K6 mRNA CTD PMID:21714911 MAP2K6 Human beta-D-glucan decreases expression EXP 6480464 beta-Glucans results in decreased expression of MAP2K6 mRNA CTD PMID:25970150 MAP2K6 Human bis(2-chloroethyl) sulfide increases phosphorylation EXP 6480464 Mustard Gas results in increased phosphorylation of MAP2K6 protein CTD PMID:15251176 MAP2K6 Human bis(2-chloroethyl) sulfide affects expression ISO Map2k6 (Rattus norvegicus) 6480464 Mustard Gas affects the expression of MAP2K6 mRNA CTD PMID:15651846 MAP2K6 Human bis(2-ethylhexyl) phthalate decreases expression ISO Map2k6 (Mus musculus) 6480464 Diethylhexyl Phthalate results in decreased expression of MAP2K6 mRNA CTD PMID:19850644 MAP2K6 Human bis(2-ethylhexyl) phthalate decreases expression EXP 6480464 Diethylhexyl Phthalate results in decreased expression of MAP2K6 mRNA CTD PMID:31163220 MAP2K6 Human bis(2-ethylhexyl) phthalate multiple interactions ISO Map2k6 (Mus musculus) 6480464 PPARA protein promotes the reaction [Diethylhexyl Phthalate results in decreased expression of MAP2K6 mRNA] CTD PMID:19850644 MAP2K6 Human bisphenol A affects expression ISO Map2k6 (Rattus norvegicus) 6480464 bisphenol A affects the expression of MAP2K6 mRNA CTD PMID:25181051 MAP2K6 Human bisphenol A multiple interactions EXP 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of MAP2K6 gene CTD PMID:31601247 MAP2K6 Human bortezomib decreases expression EXP 6480464 Bortezomib results in decreased expression of MAP2K6 mRNA CTD PMID:20977926 MAP2K6 Human bromoacetate decreases expression EXP 6480464 bromoacetate results in decreased expression of MAP2K6 mRNA CTD PMID:19753638 MAP2K6 Human cadmium dichloride multiple interactions EXP 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAP2K6 mRNA and Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K6 protein] CTD PMID:12634122 and PMID:18703135 MAP2K6 Human cadmium dichloride increases expression EXP 6480464 Cadmium Chloride results in increased expression of MAP2K6 mRNA CTD PMID:32512071 MAP2K6 Human cadmium dichloride increases phosphorylation ISO Map2k6 (Rattus norvegicus) 6480464 Cadmium Chloride results in increased phosphorylation of MAP2K6 protein CTD PMID:18021293 and PMID:18703135 MAP2K6 Human cadmium dichloride multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K6 protein] CTD PMID:18703135 MAP2K6 Human cadmium dichloride increases phosphorylation EXP 6480464 Cadmium Chloride results in increased phosphorylation of MAP2K6 protein CTD PMID:18703135 MAP2K6 Human cannabidiol affects methylation ISO Map2k6 (Rattus norvegicus) 6480464 Cannabidiol affects the methylation of MAP2K6 gene CTD PMID:30521419 MAP2K6 Human carbamazepine affects expression EXP 6480464 Carbamazepine affects the expression of MAP2K6 mRNA CTD PMID:24752500 MAP2K6 Human carbon nanotube decreases expression ISO Map2k6 (Mus musculus) 6480464 Nanotubes and Carbon results in decreased expression of MAP2K6 mRNA CTD PMID:25554681 and PMID:25620056 MAP2K6 Human CGP 52608 multiple interactions EXP 6480464 CGP 52608 promotes the reaction [RORA protein binds to MAP2K6 gene] CTD PMID:28238834 MAP2K6 Human chenodeoxycholic acid multiple interactions EXP 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA more ... CTD PMID:32152650 and PMID:33819548 MAP2K6 Human cisplatin affects response to substance EXP 6480464 MAP2K6 protein affects the susceptibility to Cisplatin CTD PMID:16217747 MAP2K6 Human cisplatin multiple interactions EXP 6480464 Cisplatin promotes the reaction [jinfukang results in increased expression of MAP2K6 mRNA] and jinfukang promotes the reaction [Cisplatin results in increased expression of MAP2K6 mRNA] CTD PMID:27392435 MAP2K6 Human cisplatin increases expression EXP 6480464 Cisplatin results in increased expression of MAP2K6 mRNA CTD PMID:27392435 MAP2K6 Human cisplatin multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 trichostatin A inhibits the reaction [Cisplatin results in decreased expression of MAP2K6 mRNA] CTD PMID:23558232 MAP2K6 Human cisplatin decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Cisplatin results in decreased expression of MAP2K6 mRNA CTD PMID:23558232 MAP2K6 Human cisplatin decreases response to substance ISO Map2k6 (Rattus norvegicus) 6480464 MAP2K6 protein results in decreased susceptibility to Cisplatin CTD PMID:19578154 MAP2K6 Human copper atom multiple interactions EXP 6480464 [Chelating Agents binds to Copper] which results in decreased expression of MAP2K6 mRNA more ... CTD PMID:20971185 more ... MAP2K6 Human copper(0) multiple interactions EXP 6480464 [Chelating Agents binds to Copper] which results in decreased expression of MAP2K6 mRNA more ... CTD PMID:20971185 more ... MAP2K6 Human copper(II) sulfate decreases expression EXP 6480464 Copper Sulfate results in decreased expression of MAP2K6 mRNA CTD PMID:19549813 MAP2K6 Human corn oil affects expression ISO Map2k6 (Rattus norvegicus) 6480464 Corn Oil affects the expression of MAP2K6 mRNA CTD PMID:16360708 MAP2K6 Human crocidolite asbestos decreases expression EXP 6480464 Asbestos and Crocidolite results in decreased expression of MAP2K6 mRNA CTD PMID:18687144 MAP2K6 Human cyclosporin A decreases expression EXP 6480464 Cyclosporine results in decreased expression of MAP2K6 mRNA CTD PMID:20106945 more ... MAP2K6 Human cyclosporin A multiple interactions EXP 6480464 [Cyclosporine co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 MAP2K6 Human cyclosporin A increases expression EXP 6480464 Cyclosporine results in increased expression of MAP2K6 mRNA CTD PMID:27989131 MAP2K6 Human D-glucose multiple interactions EXP 6480464 [MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Glucose CTD PMID:27278863 MAP2K6 Human DDT multiple interactions EXP 6480464 MAP2K6 protein promotes the reaction [DDT results in increased activity of NOTCH1 protein] CTD PMID:18791200 MAP2K6 Human deoxycholic acid multiple interactions EXP 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA more ... CTD PMID:32152650 and PMID:33819548 MAP2K6 Human deoxynivalenol increases phosphorylation EXP 6480464 deoxynivalenol results in increased phosphorylation of MAP2K6 protein CTD PMID:20181660 MAP2K6 Human deoxynivalenol multiple interactions EXP 6480464 AG 1879 inhibits the reaction [deoxynivalenol results in increased phosphorylation of MAP2K6 protein] CTD PMID:20181660 MAP2K6 Human dexamethasone decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Dexamethasone results in decreased expression of MAP2K6 mRNA CTD PMID:20032058 MAP2K6 Human dexamethasone multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Testosterone inhibits the reaction [Dexamethasone results in decreased expression of MAP2K6 mRNA] CTD PMID:20032058 MAP2K6 Human diarsenic trioxide multiple interactions ISO Map2k6 (Mus musculus) 6480464 MAP2K6 protein promotes the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAPK14 protein] CTD PMID:16818652 MAP2K6 Human diarsenic trioxide affects response to substance ISO Map2k6 (Mus musculus) 6480464 MAP2K6 protein affects the susceptibility to Arsenic Trioxide CTD PMID:16818652 MAP2K6 Human diarsenic trioxide multiple interactions EXP 6480464 Arsenic Trioxide results in increased phosphorylation of and results in increased activity of MAP2K6 protein CTD PMID:16818652 MAP2K6 Human diarsenic trioxide decreases expression EXP 6480464 Arsenic Trioxide results in decreased expression of MAP2K6 mRNA CTD PMID:26705709 MAP2K6 Human dibenz[a,h]anthracene increases expression ISO Map2k6 (Mus musculus) 6480464 1 more ... CTD PMID:26377693 MAP2K6 Human dibutyl phthalate decreases expression ISO Map2k6 (Mus musculus) 6480464 Dibutyl Phthalate results in decreased expression of MAP2K6 mRNA CTD PMID:21266533 MAP2K6 Human dibutyl phthalate decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Dibutyl Phthalate results in decreased expression of MAP2K6 mRNA CTD PMID:21266533 MAP2K6 Human dichloroacetic acid decreases expression ISO Map2k6 (Mus musculus) 6480464 Dichloroacetic Acid results in decreased expression of MAP2K6 mRNA CTD PMID:28962523 MAP2K6 Human dichromium trioxide multiple interactions EXP 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAP2K6 mRNA CTD PMID:12634122 MAP2K6 Human diclofenac affects expression EXP 6480464 Diclofenac affects the expression of MAP2K6 mRNA CTD PMID:24752500 MAP2K6 Human dicrotophos decreases expression EXP 6480464 dicrotophos results in decreased expression of MAP2K6 mRNA CTD PMID:28302478 MAP2K6 Human Didecyldimethylammonium decreases expression EXP 6480464 didecyldimethylammonium results in decreased expression of MAP2K6 mRNA CTD PMID:32763356 MAP2K6 Human disodium selenite decreases expression EXP 6480464 Sodium Selenite results in decreased expression of MAP2K6 mRNA CTD PMID:16705456 MAP2K6 Human disodium selenite increases expression EXP 6480464 Sodium Selenite results in increased expression of MAP2K6 mRNA CTD PMID:18175754 MAP2K6 Human diuron decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Diuron results in decreased expression of MAP2K6 mRNA CTD PMID:21551480 MAP2K6 Human dorsomorphin multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 MAP2K6 Human doxorubicin affects activity EXP 6480464 Doxorubicin affects the activity of MAP2K6 protein CTD PMID:15870702 MAP2K6 Human doxorubicin affects methylation ISO Map2k6 (Rattus norvegicus) 6480464 Doxorubicin affects the methylation of MAP2K6 gene CTD PMID:28962528 MAP2K6 Human endosulfan decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Endosulfan results in decreased expression of MAP2K6 mRNA CTD PMID:29391264 MAP2K6 Human entinostat decreases expression EXP 6480464 entinostat results in decreased expression of MAP2K6 mRNA CTD PMID:26272509 MAP2K6 Human epoxiconazole decreases expression ISO Map2k6 (Mus musculus) 6480464 epoxiconazole results in decreased expression of MAP2K6 mRNA CTD PMID:35436446 MAP2K6 Human ethanol affects expression ISO Map2k6 (Mus musculus) 6480464 Ethanol affects the expression of MAP2K6 mRNA CTD PMID:30319688 MAP2K6 Human filipin III multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Filipin inhibits the reaction [ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]] more ... CTD PMID:17172471 MAP2K6 Human folic acid decreases expression EXP 6480464 Folic Acid results in decreased expression of MAP2K6 mRNA CTD PMID:21867686 MAP2K6 Human FR900359 increases phosphorylation EXP 6480464 FR900359 results in increased phosphorylation of MAP2K6 protein CTD PMID:37730182 MAP2K6 Human fulvestrant multiple interactions EXP 6480464 [bisphenol A co-treated with Fulvestrant] results in decreased methylation of MAP2K6 gene and MAP2K6 promotes the reaction [Fulvestrant results in decreased expression of GJA1 protein] CTD PMID:29180066 and PMID:31601247 MAP2K6 Human gemcitabine increases phosphorylation EXP 6480464 Gemcitabine results in increased phosphorylation of MAP2K6 protein CTD PMID:15003513 MAP2K6 Human genistein decreases expression EXP 6480464 Genistein results in decreased expression of MAP2K6 mRNA CTD PMID:26865667 MAP2K6 Human gentamycin decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Gentamicins results in decreased expression of MAP2K6 mRNA CTD PMID:33387578 MAP2K6 Human glucose multiple interactions EXP 6480464 [MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Glucose CTD PMID:27278863 MAP2K6 Human glycochenodeoxycholic acid multiple interactions EXP 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA more ... CTD PMID:32152650 and PMID:33819548 MAP2K6 Human glycocholic acid multiple interactions EXP 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA more ... CTD PMID:32152650 and PMID:33819548 MAP2K6 Human glycodeoxycholic acid multiple interactions EXP 6480464 [Atazanavir Sulfate co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA more ... CTD PMID:32152650 and PMID:33819548 MAP2K6 Human glyphosate decreases expression EXP 6480464 Glyphosate results in decreased expression of MAP2K6 mRNA CTD PMID:31295307 MAP2K6 Human hydrogen peroxide affects expression EXP 6480464 Hydrogen Peroxide affects the expression of MAP2K6 mRNA CTD PMID:20044591 MAP2K6 Human iron atom multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]] more ... CTD PMID:17172471 MAP2K6 Human iron atom increases phosphorylation ISO Map2k6 (Rattus norvegicus) 6480464 Iron results in increased phosphorylation of MAP2K6 protein CTD PMID:17172471 MAP2K6 Human iron dichloride decreases expression EXP 6480464 ferrous chloride results in decreased expression of MAP2K6 mRNA CTD PMID:35984750 MAP2K6 Human iron(0) multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Filipin inhibits the reaction [Iron promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein]] more ... CTD PMID:17172471 MAP2K6 Human iron(0) increases phosphorylation ISO Map2k6 (Rattus norvegicus) 6480464 Iron results in increased phosphorylation of MAP2K6 protein CTD PMID:17172471 MAP2K6 Human iron(2+) sulfate (anhydrous) multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 ferrous sulfate promotes the reaction [MAP3K7 protein results in increased phosphorylation of MAP2K6 protein] more ... CTD PMID:17172471 MAP2K6 Human iron(2+) sulfate (anhydrous) increases phosphorylation ISO Map2k6 (Rattus norvegicus) 6480464 ferrous sulfate results in increased phosphorylation of MAP2K6 protein CTD PMID:17172471 MAP2K6 Human L-ascorbic acid multiple interactions EXP 6480464 Ascorbic Acid inhibits the reaction [Fenretinide results in increased phosphorylation of MAP2K6 protein] CTD PMID:16407847 MAP2K6 Human lead diacetate multiple interactions EXP 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAP2K6 mRNA CTD PMID:12634122 MAP2K6 Human lipopolysaccharide multiple interactions ISO Map2k6 (Mus musculus) 6480464 IRAK2 protein promotes the reaction [Lipopolysaccharides results in increased activity of MAP2K6 protein] CTD PMID:21291324 MAP2K6 Human lipopolysaccharide increases activity ISO Map2k6 (Mus musculus) 6480464 Lipopolysaccharides results in increased activity of MAP2K6 protein CTD PMID:21291324 MAP2K6 Human lycopene decreases expression EXP 6480464 lycopene results in decreased expression of MAP2K6 protein CTD PMID:17337101 MAP2K6 Human maneb multiple interactions ISO Map2k6 (Mus musculus) 6480464 [Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA more ... CTD PMID:23963992 MAP2K6 Human melatonin multiple interactions ISO Map2k6 (Mus musculus) 6480464 Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA] CTD PMID:23963992 MAP2K6 Human mercury dibromide decreases expression EXP 6480464 mercuric bromide results in decreased expression of MAP2K6 mRNA CTD PMID:26272509 MAP2K6 Human mercury dibromide multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human mercury dichloride decreases expression EXP 6480464 Mercuric Chloride results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human methimazole decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Methimazole results in decreased expression of MAP2K6 mRNA CTD PMID:30047161 MAP2K6 Human methotrexate affects response to substance EXP 6480464 MAP2K6 protein affects the susceptibility to Methotrexate CTD PMID:16217747 MAP2K6 Human methotrexate decreases expression EXP 6480464 Methotrexate results in decreased expression of MAP2K6 mRNA CTD PMID:19100307 MAP2K6 Human methylmercury chloride decreases expression EXP 6480464 methylmercuric chloride results in decreased expression of MAP2K6 mRNA CTD PMID:26272509 and PMID:28001369 MAP2K6 Human mevinphos increases phosphorylation ISO Map2k6 (Rattus norvegicus) 6480464 Mevinphos results in increased phosphorylation of MAP2K6 protein CTD PMID:23157661 MAP2K6 Human mono(2-ethylhexyl) phthalate decreases expression EXP 6480464 mono-(2-ethylhexyl)phthalate results in decreased expression of MAP2K6 mRNA CTD PMID:36695872 MAP2K6 Human N,N-diethyl-m-toluamide multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 [Permethrin co-treated with DEET] results in increased methylation of MAP2K6 gene CTD PMID:33148267 MAP2K6 Human N-acetyl-L-cysteine multiple interactions EXP 6480464 Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K6 protein] CTD PMID:18703135 MAP2K6 Human N-acetyl-L-cysteine multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Acetylcysteine inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAP2K6 protein] CTD PMID:18703135 MAP2K6 Human N-methyl-4-phenylpyridinium multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 CIB1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased phosphorylation of MAP2K6 protein] CTD PMID:28939911 MAP2K6 Human N-methyl-4-phenylpyridinium increases phosphorylation ISO Map2k6 (Rattus norvegicus) 6480464 1-Methyl-4-phenylpyridinium results in increased phosphorylation of MAP2K6 protein CTD PMID:28939911 MAP2K6 Human nefazodone multiple interactions EXP 6480464 [nefazodone co-treated with Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid] results in decreased expression of MAP2K6 mRNA CTD PMID:32152650 MAP2K6 Human nickel dichloride affects expression ISO Map2k6 (Rattus norvegicus) 6480464 nickel chloride affects the expression of MAP2K6 mRNA CTD PMID:22110744 MAP2K6 Human nickel dichloride increases response to substance ISO Map2k6 (Mus musculus) 6480464 MAP2K6 protein results in increased susceptibility to nickel chloride CTD PMID:21544193 MAP2K6 Human nickel dichloride multiple interactions ISO Map2k6 (Mus musculus) 6480464 [incomplete Freund's adjuvant co-treated with Freund's Adjuvant co-treated with nickel chloride] results in increased expression of MAP2K6 mRNA more ... CTD PMID:21544193 and PMID:23536762 MAP2K6 Human nicotine increases expression ISO Map2k6 (Rattus norvegicus) 6480464 Nicotine results in increased expression of MAP2K6 mRNA CTD PMID:20426880 MAP2K6 Human Nonylphenol increases expression EXP 6480464 nonylphenol results in increased expression of MAP2K6 protein CTD PMID:24039973 MAP2K6 Human obeticholic acid decreases expression EXP 6480464 obeticholic acid results in decreased expression of MAP2K6 mRNA CTD PMID:27939613 MAP2K6 Human organoselenium compound multiple interactions EXP 6480464 [Organoselenium Compounds binds to Copper] which results in decreased expression of MAP2K6 mRNA CTD PMID:25167922 MAP2K6 Human ouabain increases expression EXP 6480464 Ouabain results in increased expression of MAP2K6 mRNA CTD PMID:28795476 MAP2K6 Human ozone multiple interactions ISO Map2k6 (Mus musculus) 6480464 [Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in decreased expression of MAP2K6 mRNA and [Air Pollutants results in increased abundance of Ozone] which results in decreased expression of MAP2K6 mRNA CTD PMID:34911549 MAP2K6 Human p-chloromercuribenzoic acid decreases expression EXP 6480464 p-Chloromercuribenzoic Acid results in decreased expression of MAP2K6 mRNA CTD PMID:26272509 MAP2K6 Human p-chloromercuribenzoic acid multiple interactions EXP 6480464 [NOG protein co-treated with p-Chloromercuribenzoic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human p-menthan-3-ol decreases expression EXP 6480464 Menthol results in decreased expression of MAP2K6 mRNA CTD PMID:26760959 MAP2K6 Human panobinostat multiple interactions EXP 6480464 [NOG protein co-treated with Panobinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human paracetamol affects expression ISO Map2k6 (Mus musculus) 6480464 Acetaminophen affects the expression of MAP2K6 mRNA CTD PMID:17562736 MAP2K6 Human paracetamol decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Acetaminophen results in decreased expression of MAP2K6 mRNA CTD PMID:33387578 MAP2K6 Human paracetamol multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Acetaminophen] results in decreased expression of MAP2K6 mRNA CTD PMID:33819548 MAP2K6 Human paracetamol decreases expression EXP 6480464 Acetaminophen results in decreased expression of MAP2K6 mRNA CTD PMID:29067470 MAP2K6 Human paraquat multiple interactions ISO Map2k6 (Mus musculus) 6480464 [Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA more ... CTD PMID:23963992 MAP2K6 Human paraquat decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Paraquat results in decreased expression of MAP2K6 mRNA CTD PMID:32680482 MAP2K6 Human parathion increases expression ISO Map2k6 (Mus musculus) 6480464 Parathion results in increased expression of MAP2K6 mRNA CTD PMID:34813904 MAP2K6 Human perfluorohexanesulfonic acid decreases expression ISO Map2k6 (Mus musculus) 6480464 perfluorohexanesulfonic acid results in decreased expression of MAP2K6 mRNA CTD PMID:37995155 MAP2K6 Human permethrin multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 [Permethrin co-treated with DEET] results in increased methylation of MAP2K6 gene CTD PMID:33148267 MAP2K6 Human phenobarbital increases expression ISO Map2k6 (Mus musculus) 6480464 Phenobarbital results in increased expression of MAP2K6 mRNA CTD PMID:19270015 MAP2K6 Human phenobarbital affects expression ISO Map2k6 (Mus musculus) 6480464 Phenobarbital affects the expression of MAP2K6 mRNA CTD PMID:23091169 MAP2K6 Human phenylmercury acetate decreases expression EXP 6480464 Phenylmercuric Acetate results in decreased expression of MAP2K6 mRNA CTD PMID:26272509 MAP2K6 Human phenylmercury acetate multiple interactions EXP 6480464 [NOG protein co-treated with Phenylmercuric Acetate co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human phlorizin increases expression ISO Map2k6 (Mus musculus) 6480464 Phlorhizin results in increased expression of MAP2K6 mRNA CTD PMID:22538082 MAP2K6 Human phorbol 13-acetate 12-myristate multiple interactions EXP 6480464 [MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate more ... CTD PMID:27278863 MAP2K6 Human piperonyl butoxide decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Piperonyl Butoxide results in decreased expression of MAP2K6 mRNA CTD PMID:22484513 MAP2K6 Human pirinixic acid multiple interactions ISO Map2k6 (Mus musculus) 6480464 [pirinixic acid co-treated with PPARA] results in decreased expression of MAP2K6 mRNA CTD PMID:20813756 MAP2K6 Human pirinixic acid decreases expression ISO Map2k6 (Mus musculus) 6480464 pirinixic acid results in decreased expression of MAP2K6 mRNA CTD PMID:20813756 and PMID:23811191 MAP2K6 Human potassium chromate multiple interactions EXP 6480464 [potassium chromate(VI) co-treated with epigallocatechin gallate] results in decreased expression of MAP2K6 mRNA CTD PMID:22079256 MAP2K6 Human potassium chromate decreases expression EXP 6480464 potassium chromate(VI) results in decreased expression of MAP2K6 mRNA CTD PMID:22079256 MAP2K6 Human progesterone multiple interactions EXP 6480464 [Progesterone co-treated with Estradiol] results in increased expression of MAP2K6 mRNA CTD PMID:17404688 MAP2K6 Human progesterone increases expression EXP 6480464 Progesterone results in increased expression of MAP2K6 mRNA CTD PMID:17404688 MAP2K6 Human Ptaquiloside decreases expression EXP 6480464 ptaquiloside results in decreased expression of MAP2K6 mRNA CTD PMID:22143989 MAP2K6 Human quercetin increases expression EXP 6480464 Quercetin results in increased expression of MAP2K6 mRNA CTD PMID:27514524 MAP2K6 Human quercetin decreases expression EXP 6480464 Quercetin results in decreased expression of MAP2K6 mRNA CTD PMID:21632981 MAP2K6 Human raloxifene multiple interactions EXP 6480464 MAP2K6 protein promotes the reaction [Raloxifene Hydrochloride results in increased expression of HMOX1 protein] CTD PMID:20888885 MAP2K6 Human ritodrine increases expression ISO Map2k6 (Mus musculus) 6480464 Ritodrine results in increased expression of MAP2K6 mRNA CTD PMID:23370008 MAP2K6 Human rotenone decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Rotenone results in decreased expression of MAP2K6 mRNA CTD PMID:28374803 MAP2K6 Human S-(1,2-dichlorovinyl)-L-cysteine decreases expression EXP 6480464 S-(1 and 2-dichlorovinyl)cysteine results in decreased expression of MAP2K6 mRNA CTD PMID:33725128 MAP2K6 Human Salinomycin multiple interactions EXP 6480464 [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA] and [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein] CTD PMID:30796972 MAP2K6 Human SB 203580 multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 SB 203580 inhibits the reaction [MAP2K6 protein results in decreased expression of EP300 protein] CTD PMID:15767673 MAP2K6 Human SB 203580 multiple interactions EXP 6480464 SB 203580 inhibits the reaction [[MAP2K6 gene mutant form results in increased activity of MAP2K6 protein] which results in increased susceptibility to Tetradecanoylphorbol Acetate] CTD PMID:27278863 MAP2K6 Human SB 431542 multiple interactions EXP 6480464 [NOG protein co-treated with mercuric bromide co-treated with dorsomorphin co-treated with 4-(5-benzo(1 more ... CTD PMID:27188386 MAP2K6 Human Securinine decreases expression EXP 6480464 securinine results in decreased expression of MAP2K6 mRNA CTD PMID:32662633 MAP2K6 Human sevoflurane increases phosphorylation EXP 6480464 sevoflurane results in increased phosphorylation of MAP2K6 protein CTD PMID:18349187 MAP2K6 Human silicon dioxide decreases expression EXP 6480464 Silicon Dioxide analog results in decreased expression of MAP2K6 mRNA and Silicon Dioxide results in decreased expression of MAP2K6 mRNA CTD PMID:22300531 and PMID:25895662 MAP2K6 Human sodium arsenite multiple interactions EXP 6480464 [sodium arsenite co-treated with Cadmium Chloride co-treated with chromic oxide co-treated with chromous chloride co-treated with lead acetate] results in decreased expression of MAP2K6 mRNA more ... CTD PMID:12634122 and PMID:9442025 MAP2K6 Human sodium arsenite increases expression EXP 6480464 sodium arsenite results in increased expression of MAP2K6 mRNA CTD PMID:17879257 MAP2K6 Human sodium dichromate affects expression ISO Map2k6 (Rattus norvegicus) 6480464 sodium bichromate affects the expression of MAP2K6 mRNA CTD PMID:22110744 MAP2K6 Human Soman decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Soman results in decreased expression of MAP2K6 mRNA CTD PMID:19281266 MAP2K6 Human streptozocin increases expression ISO Map2k6 (Rattus norvegicus) 6480464 Streptozocin results in increased expression of MAP2K6 mRNA CTD PMID:25905778 MAP2K6 Human sulfadimethoxine decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Sulfadimethoxine results in decreased expression of MAP2K6 mRNA CTD PMID:30047161 MAP2K6 Human sulfates multiple interactions EXP 6480464 [Soot co-treated with Sulfates] affects the methylation of MAP2K6 promoter CTD PMID:25395096 MAP2K6 Human sulforaphane decreases expression EXP 6480464 sulforaphane results in decreased expression of MAP2K6 mRNA CTD PMID:26833863 and PMID:31838189 MAP2K6 Human Sunset Yellow FCF multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with 6-hydroxy-5-((p- sulfophenyl)azo)-2-naphthalenesulfonic acid disodium salt] results in increased expression of MAP2K6 mRNA CTD PMID:33819548 MAP2K6 Human tanespimycin multiple interactions EXP 6480464 [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP mRNA] and [salinomycin co-treated with tanespimycin] inhibits the reaction [MAP2K6 protein results in increased expression of TYMP protein] CTD PMID:30796972 MAP2K6 Human tartrazine multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Tartrazine] results in decreased expression of MAP2K6 mRNA CTD PMID:33819548 MAP2K6 Human tert-butyl hydroperoxide increases phosphorylation EXP 6480464 tert-Butylhydroperoxide results in increased phosphorylation of MAP2K6 protein CTD PMID:17003459 MAP2K6 Human testosterone multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 Testosterone inhibits the reaction [Dexamethasone results in decreased expression of MAP2K6 mRNA] CTD PMID:20032058 MAP2K6 Human tetrachloromethane decreases expression ISO Map2k6 (Mus musculus) 6480464 Carbon Tetrachloride results in decreased expression of MAP2K6 mRNA CTD PMID:31919559 MAP2K6 Human thioacetamide decreases expression ISO Map2k6 (Rattus norvegicus) 6480464 Thioacetamide results in decreased expression of MAP2K6 mRNA CTD PMID:23411599 and PMID:34492290 MAP2K6 Human thiram decreases expression EXP 6480464 Thiram results in decreased expression of MAP2K6 mRNA CTD PMID:38568856 MAP2K6 Human trichostatin A multiple interactions ISO Map2k6 (Rattus norvegicus) 6480464 trichostatin A inhibits the reaction [Cisplatin results in decreased expression of MAP2K6 mRNA] CTD PMID:23558232 MAP2K6 Human trichostatin A multiple interactions EXP 6480464 [NOG protein co-treated with trichostatin A co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human trichostatin A decreases expression EXP 6480464 trichostatin A results in decreased expression of MAP2K6 mRNA CTD PMID:24935251 and PMID:26272509 MAP2K6 Human trichostatin A increases expression EXP 6480464 trichostatin A results in increased expression of MAP2K6 mRNA CTD PMID:24935251 MAP2K6 Human trichostatin A increases expression ISO Map2k6 (Rattus norvegicus) 6480464 trichostatin A results in increased expression of MAP2K6 mRNA CTD PMID:23558232 MAP2K6 Human triclosan multiple interactions EXP 6480464 [Glycochenodeoxycholic Acid co-treated with Deoxycholic Acid co-treated with Chenodeoxycholic Acid co-treated with Glycodeoxycholic Acid co-treated with Glycocholic Acid co-treated with Triclosan] results in decreased expression of MAP2K6 mRNA CTD PMID:33819548 MAP2K6 Human trimethyltin decreases expression ISO Map2k6 (Mus musculus) 6480464 trimethyltin results in decreased expression of MAP2K6 mRNA CTD PMID:21435392 MAP2K6 Human Triptolide decreases expression ISO Map2k6 (Mus musculus) 6480464 triptolide results in decreased expression of MAP2K6 mRNA CTD PMID:32835833 MAP2K6 Human tris(2-butoxyethyl) phosphate affects expression EXP 6480464 tris(2-butoxyethyl) phosphate affects the expression of MAP2K6 mRNA CTD PMID:29024780 MAP2K6 Human troglitazone decreases expression EXP 6480464 troglitazone results in decreased expression of MAP2K6 mRNA CTD PMID:19140230 MAP2K6 Human trovafloxacin decreases expression ISO Map2k6 (Mus musculus) 6480464 trovafloxacin results in decreased expression of MAP2K6 mRNA CTD PMID:35537566 MAP2K6 Human urethane decreases expression EXP 6480464 Urethane results in decreased expression of MAP2K6 mRNA CTD PMID:28818685 MAP2K6 Human valproic acid increases expression EXP 6480464 Valproic Acid results in increased expression of MAP2K6 mRNA CTD PMID:24935251 and PMID:29154799 MAP2K6 Human valproic acid multiple interactions EXP 6480464 [NOG protein co-treated with Valproic Acid co-treated with dorsomorphin co-treated with 4-(5-benzo(1 and 3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP2K6 mRNA CTD PMID:27188386 MAP2K6 Human valproic acid decreases expression EXP 6480464 Valproic Acid results in decreased expression of MAP2K6 mRNA CTD PMID:23179753 more ... MAP2K6 Human vanadium atom increases expression EXP 6480464 Vanadium results in increased expression of MAP2K6 mRNA CTD PMID:19000753 MAP2K6 Human vanadium(0) increases expression EXP 6480464 Vanadium results in increased expression of MAP2K6 mRNA CTD PMID:19000753